Moneycontrol Be a Pro
Get App
Last Updated : Dec 31, 2018 02:04 PM IST | Source: Moneycontrol.com

Cadila Healthcare gains over 1% on USFDA approval for anti-acne cream

Clindamycin is an antibiotic that stops the growth of acne-causing bacteria. Benzoyl peroxide can also stop the growth of bacteria as well as reduce oil production in the skin.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare shares gained 1.5 percent intraday Monday after Zydus received approval from the US health regulator for anti-acne drug.

Zydus Cadila has received the final approval from the US Food and Drug Administration to market Clindamycin Phosphate and Benzoyl Peroxide gel, which is available in the 1.2 /5 percent strength.

This combination medication is used to treat a certain type of acne (inflammatory acne vulgaris). It helps to decrease the number of acne pimples.

Close

Clindamycin is an antibiotic that stops the growth of acne-causing bacteria. Benzoyl peroxide can also stop the growth of bacteria as well as reduce oil production in the skin.

The drug will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.

Cadila said the group now has 242 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY04.

At 13:34 hours IST, the stock was quoting at Rs 348.45, up Rs 3.80, or 1.10 percent on the BSE.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Dec 31, 2018 02:04 pm
Loading...
Sections
Follow us on
Available On